A Single Dose, 2-Period, 2-Treatment, 2-Way Crossover Bioequivalency Study of Anastrozole 1 mg Tablets Under Fed Conditions
- No clinically significant abnormal findings on the physical examination, medical
history, or clinical laboratory results during screening
- Positive test for HIV, Hepatitis B, or Hepatitis C.
- Treatment with known enzyme altering drugs.
- History of allergic or adverse response to anastrozole or any comparable or similar
Type of Study:
Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment
bioequivalence determined by statistical comparison Cmax
Outcome Time Frame:
Dennis Morrison, D.O.
Bio-Kinetic Clincial Applications
United States: Institutional Review Board
- Breast Cancer
- Breast Neoplasms
|Bio-Kinetic Clinical Applications||Springfield, Missouri 65802|